MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs. Get a FREE Light Plan Today! [email protected] www.valoya.com Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl MEDICAL CANNABIS IN EUROPE: THE MARKETS AND OPPORTUNITY One year after the first edition of this report, Europe continues being a key region for international cannabis companies trying to scale globally and a place that has provided numerous opportunities to local entrepreneurs. With a population of more than 500 million, generally high per-capita gross domestic product (GDP) and health-insurance coverage for cannabis in several countries, Europe is seen by many in the industry as having the potential to one day be a larger market long term than the U.S. and Canada combined. How things evolved in Europe in the past year adds to that optimistic outlook, with sales Alfredo Pascual in Germany and Italy—the two largest markets on the continent—posting double-digit, MJBizDaily International Analyst year-over-year growth in 2019. While the long-term expectation of Europe being a massive medical—and, eventually, recreational—cannabis industry continues to show promise, this report highlights the reality of the market today, including the actual sales and the regulatory frameworks that exist in the main European markets. For 2019, Marijuana Business Daily estimates total sales of medical cannabis in Europe ranged from 230 million and 250 million euros ($251 million-$273 million), with roughly half those figures represented by the markup pharmacies in countries such as Germany and Italy added before dispensing the products. For context, total medical cannabis sales in Europe in 2019 were less than half the sales that took place in the U.S. state of Arizona (population 7.3 million) last year. The European market also continues to present a unique set of challenges for companies and investors looking to make inroads there. The continent cannot be viewed as a single jurisdiction, because a diversity of languages and cultures exist across national boundaries. Meaningful European-wide regulations are scarce, and individual cannabis frameworks vary drastically. This report provides industry leaders and investors interested in the European markets with a realistic estimate of current market sizes and a detailed analysis of the countries where the most opportunities exist. What it will not provide is long-term, uncertain projections that have no basis in data. 5 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl In 2019, sales of medical cannabis in Europe continued to be centered on Germany. Other countries showed positive signs, advancing with legislation that either allowed national production or prescription, but those markets are far from developed. For producers of medical cannabis that are able to comply with stringent quality requirements, exporting to Germany continues to be the most obvious option, as the country will depend exclusively on imports until at least the end of 2020 to meet its domestic demand. However, one year after the first edition of this report, we no longer have a solid sense of the ever-growing number of countries and companies trying to export to Germany— there are just too many of them. At the same time, the number of actual companies whose products reach German patients remains just a few and largely unchanged from last year edition. It’s important to note that whenever we mention medical cannabis in Europe, we are referring to products prescribed by physicians and typically dispensed in pharmacies. Industrial hemp and low-THC CBD consumer products are not part of this report, which also doesn’t cover noncommercial access to cannabis, for instance, through home growing or marijuana social clubs. Because of the ever-changing nature of cannabis regulations and the fact most available official sales data is only through the end of 2019 for most jurisdictions at the time of publication, information in this report should be assumed to be updated through 2019 unless otherwise specified. I’d like to give a special thank you to the government agencies and officials that provided official data or clarifications, and to all the local experts and industry insiders who helped to make this comprehensive report possible, including Andrew de Roy for his insights on Poland. If you have any questions or comments, feel free to reach out to me at [email protected]. Alfredo Pascual International Analyst 6 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. Leading German manufacturer, importer, and distributor of medical cannabis THE COMPANY OUR BUSINESS MODEL Founded in 2017, Cansativa is a GMP-certified Global footprint – We source medical pharmaceutical company and holds a GDP cannabis globally and collaborate with pharmaceutical wholesale license to trade in several high-class and well-known controlled substances. From its headquarters in medical cannabis suppliers Mörfelden-Walldorf, Germany, Cansativa and its subsidiaries work to professionalize the medical One-stop shop – We positioned Can- cannabis market, eliminate stigmatization and to sativa as the leading medical cannabis permanently serve patients needs. As an owner- focused wholesaler with an extensive managed company, our growth target is linked to customer base and a broad product a long-term vision – continuously setting industry- portfolio to serve patients needs wide benchmarks. Know-how – Due to our professional Since the very beginning, Cansativa has operated integrated inhouse solutions we became its own distribution and fulfillment center, and as experts within the European medical one of its industry’s “first movers”, it has become a cannabis industry leading manufacturer, importer and distributor of medical cannabis in Germany. From its locations Patients first – Our top priority is in Mörfelden-Walldorf and Frankfurt am Main, the process and product quality without company supplies pharmacies and pharmaceutical compromises to ensure a save product wholesalers nationwide. CONTACT US! www.cansativa.de or send an email to [email protected] Founding of Cansativa GmbH in Receival of EU GMP manufacturing Frankfurt am Main and receival of and import license for both EU GDP wholesale license. Cansativa GmbH facilities 2017 2018 2019 2020 Processing of first import Became leading medical cannabis one-stop and start of operations shop with an extensive product portfolio Johann Benedikt Sons Jakob Christian Sons Chief Executive Officer and Founder General Counsel and Founder © Cansativa GmbH Hessenring 15i 64546 Mörfelden-Walldorf www.cansativa.de Die Cansativa GmbH mit Sitz in Frankfurt am Main ist eingetragen im Handelsregister des Amtsgerichtes Frankfurt am Main unter HRB 108385. beyond pioneering Health, especially in these strange and uncertain times, has become everyone’s primary concern. We are therefore grateful that the production and distribution of Bedrocan’s medicinal cannabis to patients around the world will continue as usual. In fact, in some countries, new distribution channels have emerged to meet the needs of vulnerable patients. Also during a crisis like the COVID-19 pandemic, we are committed to deliver standardised cannabis of Bedrocan is the oldest company in the world to pharmaceutical quality. Each product has a distinct provide several chemically different cannabis chemical profile, with a consistent, defined